Navigation Links
High-throughput gene expression analysis to screen for anti-asthma drugs

Andreas Pahl, Uwe Oelmller,* and Susanne Ullmann*
Department of Pharmacology, University of Erlangen, Erlangen, Germany

* QIAGEN GmbH, Hilden Germany Drug library screening based on gene expression analysis requires reliable and reproducible methods of RNA purification and sensitive, quantitative, real-time RT-PCR analysis. This article demonstrates how RNeasy 96 technology, automated on the BioRobot Gene Expression workstation, enabled reproducible, high-throughput sample preparation. One-step, real-time RT-PCR using the QuantiTect Probe RT-PCR Kit provided highly sensitive gene expression analysis to identify potential drugs to fight asthma.

Bronchial asthma is one of the commonest chronic diseases in modern society and the most common chronic childhood disease. The pathogenesis and causes of asthma are still poorly understood. Nonetheless, our knowledge of asthma pathogenesis has increased greatly over the past two decades, partially through recognition of the critical role played by cytokines in the inflammatory response.

Many cytokines are involved in asthma. Although some of these cytokines are involved in many inflammatory diseases, others are more specific to allergic inflammation, such as asthma. These cytokines include interleukins (IL) IL-4 and IL-13, which are derived from T-helper 2 (Th2) cells. Th1 cells, which are involved in cellular immunity, secrete other cytokines, such as IL-2. Gene expression analysis of these cytokines provides valuable information about the effects of potential drugs for asthma.

The goal of our research is to identify potential new drugs that selectively inhibit expression of specific cytokines. High-throughput RNeasy 96 RNA isolation technology automated on the BioRobot Gene Expression workstation and real-time RT-PCR analysis using the QuantiTect Probe RT-PCR Kit enable
sensitive analysis of cytokine gene expression. These technologies speed the progresstoward new specific drugs to fight asthma.

Materials and methods

Peripheral blood monocytes (PBMCs) were grown in 96-well plates with 200,000 cells per well. The cells were treated with different drug candidates for 30 minutes. TPA/ Ionomycin was then added to stimulate Th1 and Th2 cells, and the cells were incubated for a further 4 hours. Unstimulated cells were used as a control for basal gene expression levels. The cell cultures were then placed on the BioRobot Gene Expression workstation for fully automated RNA purification using the RNeasy 96 BioRobot 8000 Kit. Quantitative, real-time RT-PCR of cytokine transcripts was carried out in 384-well format on the ABI PRISM 7900HT Sequence Detection System using the QuantiTect Probe RT-PCR Kit.

Results and discussion

Automated RNA isolation on the BioRobot Gene Expression workstation and quantification by one-step, real-time QuantiTect Probe RT-PCR enable creening of large numbers of synthetic and natural substances for their effects on cytokine expression in cells. We have used this approach to screen for asthma drugs that inhibit expression of Th2-specific cytokines (1). Figure 1 shows an example using cyclosporine A (CSA), which was used as a control compound during the screening process. CSA is an immunosuppressive agent known to inhibit transcription of IL-2 and used to prevent organ transplant rejection. Expression of IL-2 mRNA was essentially inhibited by treatment with CSA. Expression of Th2 specific IL-13 mRNA was reduced to a lesser extent in the CSA-treated cells, and IL-4 mRNA expression was the same in unstimulated cells and CSA-treated cells, indicating that the drug prevented the stimulation-dependent increase in gene expression. Expression of -actin mRNA, used as a housekeeping transcript control, remained unchanged.

High-Throughput Screening of Cytokine Expression Figure 1 PBMCs were stimulated with TPA/lonomycin or unstimulated, and treated with CSA or not treated, as indicated (see Materials and methods). Total RNA was isolated using RNeasy 96 technology, fully automated on the BioRobot Gene Expression workstation. Real-time, quantitative, one-step RT-PCR was carried out in a 384-well format using the QuantiTect Probe RT-PCR Kit and primers and probes specific for the transcripts indicated. All reactions were carried out with 2 to 4 replicates. Threshold cycles are indicated. Conclusions
  • Fully automated RNeasy 96 technology on the BioRobot Gene Expression workstation enabled walkaway operation for high throughput drug screening applications.
  • Quantitative, real-time, one-step RT-PCR using the QuantiTect Probe RT-PCR Kit provided highly sensitive results to analyze expression of different cytokines in response to drug candidates.
  • High-throughput drug screening using these technologies enables identification of specific potential drugs to combat asthma.

Reference
1. Pahl, A. (2002) Manuscript in preparation.




'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Quantitative end-point RT-PCR gene expression measurement using the Agilent 2100 Bioanalyzer and standardized RT-PCR
2. Laser Capture Microdissection of muscle fiber populations and expression analysis by RT-PCR
3. Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives in the yeast Saccharomyces cerevisiae: Detection in vivo using the Varian Cary Eclipse
4. Successful stabilization of gene expression profiles
5. Fully automated DNA purification and efficient multiplex PCR for analysis of microsatellite loci
6. Flow cytometric analysis of human primary cells using the Agilent 2100 bioanalyzer and on-chip staining
7. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
8. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
9. Microfluidic analysis of multiplex PCR products for the genotyping of Helicobacter pylori
10. High resolution DNA analysis with the DNA 500 and DNA 1000 LabChip kits
11. Extended data analysis using DeCyder EDA
Post Your Comments:
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), ... that target the underlying mechanisms of cancer, today reported ... December 31, 2014. Effective July 17, 2014, ... 31 to December 31. As a result of that ... the quarter and the seven months ended December 31, ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut Scott ... this month to spend a year living and working on ... interviews from 5:30 to 7 a.m. EDT Monday, March 9. ... as he completes the final weeks of his training. ... video on NASA Television highlighting his mission training and previous ...
Breaking Biology Technology:Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... coincide with Sleep Awareness WeekSAN CARLOS, Calif., March 3 ... America,s wallets--it,s hurt sleep habits as well. According to ... poll, nearly one-third of Americans have lost sleep ... dangers of sleep loss, SleepQuest is renewing its commitment ...
... the newest version of the award-winning clinical ... which enables clinical development organizations to roll ... in minutes. The software provides instant ... and timelines across a program, business unit, ...
... and artificial sweeteners partner to produce world,s ... innovation to baking aisleINDIANAPOLIS, March 3 ... manufacturer of the patented probiotic strain GanedenBC30, ... Heartland Sweeteners , an Indianapolis-based leading innovator ...
Cached Biology Technology:SleepQuest Continues to Fight for Sleep Apnea Education 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 3
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/10/2015)...  Alere Inc. (NYSE: ALR), a global leader ... the quarter ended December 31, 2014. ... Alere said, "We made substantial progress in the ... leader in rapid diagnostics and delivering against our ... in early January enabled us to substantially reduce ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... continents have engineered an efficient and environmentally friendly catalyst ... used extensively in modern industry to manufacture fertilizer and ... abundant element, it is generally not found as the ... water (H2O) or to carbon in methane (CH4), the ...
... tool may be able to improve its specificity. ... Nature Biotechnology , Massachusetts General Hospital (MGH) investigators describe ... (gRNA) component of the synthetic enzymes called CRISPR-Cas RNA-guided ... mutations at sites other than the intended target, a ...
... have discovered that breast stem cells and their ,daughters, ... are active in puberty and throughout life. The ... that they could harbour genetic defects or damage that ... timeline of breast cancer development. The finding is also ...
Cached Biology News:Engineers teach old chemical new tricks to make cleaner fuels, fertilizers 2Engineers teach old chemical new tricks to make cleaner fuels, fertilizers 3Engineers teach old chemical new tricks to make cleaner fuels, fertilizers 4Shortening guide RNA markedly improves specificity of CRISPR-Cas nucleases 2Long-lived breast stem cells could retain cancer legacy 2
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen KLH-conjugated, ... acids 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse ... mapped to amino acids 62-75. ... Routinely evaluated by immunoblot. ...
Request Info...
Biology Products: